Table 3 Distribution of CKD patients in all four arms of RE-DUAL PCI trial [36]
Characteristic | Dabigatran 110 dual-therapy (n = 981), n (%) | Warfarin triple-therapy (n = 981), n (%) | Dabigatran 150 dual-therapy (n = 763), n (%) | Warfarin triple-therapy (n = 764), n (%) |
|---|---|---|---|---|
History of renal disease | 157 (16.0) | 188 (19.2) | 116 (15.2) | 115 (15.1) |